Enforcement Report - Week of April 20, 2022
Enforcement Report - Week of August 25, 2021
NEW YORK and ATLANTA, Dec. 28, 2020 /PRNewswire/ -- Peak Pharma Commercial Partners, a New York City-based investment fund dedicated to the acquisition and growth of branded, generic and over-the-counter pharmaceutical products (www.peakpharmapartners.com). announced today the creation and start of operations of Resilia Pharmaceuticals, Inc.
MAHWAH, N.J., Dec. 18, 2018 /PRNewswire/ -- Glenmark Pharmaceuticals, a research-led global integrated pharmaceutical company, today announced its foray into the branded dermatology segment in the United States. The branded portfolio for the US market will be developed and commercialized by Glenmark Therapeutics Inc., USA, which is a wholly owned subsidiary of Glenmark Holding, SA. This represents an important step in the company's long-term strategy to build a robust branded business in the US, alongside the company's existing and successful generics business.
Mylan`s Generic Econazole Nitrate Receives Approval In US